National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$59.95
add to cart

Rights & Permissions

topleft topright

Dietary Supplements: A Framework for Evaluating Safety (2005)
Institute of Medicine (IOM)

Citation Manager

. "4 Categories of Scientific Evidence--Human Information and Data." Dietary Supplements: A Framework for Evaluating Safety. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
141
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Dietary Supplements: A Framework for Evaluating Safety

TABLE 4-3 Relative Spectrum of Concern Raised by Historical Evidence of Toxicity

Increasing Concern

Traditional cautions (contraindications) exist regarding use in certain populations or circumstances

Traditional cautions (contraindications) exist regarding use in certain populations or circumstances that, if ignored, might be associated with a serious adverse effect (e.g., do not use during pregnancy)

There is clear evidence that traditional use causes conditions considered to be serious adverse events (e.g., hallucination, lethal poisoning)

gested, if a different plant part is now used, if the ingredient is formulated or processed differently, or if a different population is using the substance, then the level of concern should be raised. It is clear from these questions that historical use of a substance, even widespread historical use without documented ill effects, is no guarantor of long-term safety.

Historical use information is very useful when it describes a relationship between untoward effects and an ingested substance, as illustrated in Table 4-3. It is less useful in predicting safe use, especially if there are other reasons to be concerned about the possibility of effects that do not occur immediately following exposure. However, in the absence of other data that raise concerns about the safety of the substance, information about safe historical use may provide indirect evidence for lack of serious acute harmful effects if its relevance to current use conditions is carefully considered.

Information about the historical use of an ingredient may be most useful if it suggests potential adverse effects that could be anticipated. It is also helpful to compare relevant historical use information with other types of information that suggest possible harm (e.g., in vitro data, animal data, other human data, or data about related substances). While the historical use information should not be considered as more important than the scientific evidence, it may be appropriate to take information about the history of use into account if years of previous use would be expected to uncover the adverse effect under consideration. In such cases, historical use information may mitigate concerns to some degree.

CLINICAL STUDIES

Clinical studies evaluate the efficacy and/or safety of health care interventions in humans. There are several types of clinical studies, which differ

Page
141
Front Matter (R1-R20)
Executive Summary (1-18)
1 Introduction and Background (19-42)
2 Approaches Used by Others and Existing Safety Frameworks (43-84)
3 The Framework (85-125)
4 Categories of Scientific Evidence--Human Information and Data (126-155)
5 Categories of Scientific Evidence--Animal Data (156-174)
6 Categories of Scientific Evidence--Information About Related Substances (175-216)
7 Categories of Scientific Evidence--In Vitro Data (217-234)
8 Interactions (235-246)
9 Vulnerable Groups and Prevalance of Use (247-252)
10 Scientific Principles for Integrating and Evaluating the Available Data (253-268)
11 Applying the Framework: Case Studies Using the Prototype Safety Monographs (269-291)
12 Factors Influencing Use of the Safety Framework (292-296)
13 Findings and Recommendations (297-306)
Appendix A: Existing Frameworks or Systems for Evaluating the Safety of Other Substances (307-315)
Appendix B: Scope of Work and Comments to Initial July 2002 Framework (316-321)
Appendix C: Plant Family Information (322-355)
Appendix D: Chaparral: Prototype Monograph Summary (356-362)
Appendix E: Glucosamine: Prototype Monograph Summary (363-366)
Appendix F: Melatonin: Prototype Monograph Summary (367-371)
Appendix G: Chromium Picolinate: Prototype Monograph Summary (372-375)
Appendix H: Saw Palmetto: Prototype Monograph Summary (376-379)
Appendix I: Shark Cartilage: Prototype Monograph Summary (380-384)
Appendix J: Prototype Focused Monograph: Review of Liver-Related Risks for Chaparral (385-449)
Appendix K: Protoype Focused Monograph: Review of Anti-Androgenic Risks of Saw Palmetto Ingestion by Women (450-477)
Appendix L: Acknowledgements (478-480)
Appendix M: Biographical Sketches of Commitee Members (481-488)
Index (489-506)